Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy

Leukemia stem cells (LSCs) sustain the disease and contribute to relapse in acute myeloid leukemia (AML). Therapies that ablate LSCs may increase the chance of eliminating this cancer in patients. To this end, we used a bioreducible lipidoid-encapsulated Cas9/single guide RNA (sgRNA) ribonucleoprote...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Tzu-Chieh, Kim, Hye Sung, Chen, Yumei, Li, Yamin, LaMere, Mark W., Chen, Caroline, Wang, Hui, Gong, Jing, Palumbo, Cal D., Ashton, John M., Kim, HaeWon, Xu, Qiaobing, Becker, Michael W., Leong, Kam W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133753/
https://www.ncbi.nlm.nih.gov/pubmed/34138728
http://dx.doi.org/10.1126/sciadv.abg3217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133753/
https://www.ncbi.nlm.nih.gov/pubmed/34138728
http://dx.doi.org/10.1126/sciadv.abg3217

Ejemplares similares